Yunsoo Kim

Array ( [id] => 19058995 [patent_doc_number] => 11938189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Compositions and methods for stabilizing protein-containing formulations [patent_app_type] => utility [patent_app_number] => 17/386385 [patent_app_country] => US [patent_app_date] => 2021-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 17079 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655198 [patent_doc_number] => 20220175663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => STABLE LIQUID ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/378025 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530217 [patent_doc_number] => 20230235287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE [patent_app_type] => utility [patent_app_number] => 18/002248 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511398 [patent_doc_number] => 20230227546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 [patent_app_type] => utility [patent_app_number] => 18/011412 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140241 [patent_doc_number] => 20210308252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/350781 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050934 [patent_doc_number] => 20240092903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ANTIBODY FORMULATION DILUENT [patent_app_type] => utility [patent_app_number] => 18/000851 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548158 [patent_doc_number] => 20220119499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => Method for the reduction of host cell proteins in affinity chromatography [patent_app_type] => utility [patent_app_number] => 17/335680 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570428 [patent_doc_number] => 20240374720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => ANTIBODY FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/928561 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483689 [patent_doc_number] => 20230210991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => ANTIBODY-CONTAINING FORMULATION [patent_app_type] => utility [patent_app_number] => 17/926313 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272987 [patent_doc_number] => 20210379185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING [patent_app_type] => utility [patent_app_number] => 17/332521 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641937 [patent_doc_number] => 20220169675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => Method for the reduction of host cell proteins in affinity chromatography [patent_app_type] => utility [patent_app_number] => 17/328408 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546747 [patent_doc_number] => 20220118088 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2022-04-21 [patent_title] => AQUEOUS PHARMACEUTICAL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/211399 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17211399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546747 [patent_doc_number] => 20220118088 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2022-04-21 [patent_title] => AQUEOUS PHARMACEUTICAL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/211399 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17211399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200153 [patent_doc_number] => 20210340248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => STABILIZED ANTIBODY COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/320693 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19456822 [patent_doc_number] => 12097291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Thermostable vaccine compositions and methods of preparing same [patent_app_type] => utility [patent_app_number] => 17/316585 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 14777 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19325996 [patent_doc_number] => 12043661 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS [patent_app_type] => utility [patent_app_number] => 17/246288 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 23252 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126228 [patent_doc_number] => 20210300996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => METHOD FOR PRODUCTION OF ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/233008 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18239082 [patent_doc_number] => 20230071393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => MATRIX BOUND VESICLES (MBV) FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME [patent_app_type] => utility [patent_app_number] => 17/904287 [patent_app_country] => US [patent_app_date] => 2021-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720454 [patent_doc_number] => 20220213174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => IVIG TREATMENTS FOR SUDDEN SONSORINEURAL HEARING LOSS [patent_app_type] => utility [patent_app_number] => 17/228473 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411786 [patent_doc_number] => 12077593 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies [patent_app_type] => utility [patent_app_number] => 17/225887 [patent_app_country] => US [patent_app_date] => 2021-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11921 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17225887 [rel_patent_id] =>[rel_patent_doc_number] =>)